Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06309225 · ClinicalTrials.gov registry record · NA

Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly

A NA study of Frailty and Oropharynx Cancer, sponsored by Omar Mahmoud.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06309225 is a NA study of Frailty and Oropharynx Cancer that is actively recruiting participants, run by Omar Mahmoud. The registered enrollment target is 20 participants, below the 1,506-participant average among 48 other Frailty trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06309225, a NA study of Frailty and Oropharynx Cancer, is actively recruiting participants, sponsored by Omar Mahmoud.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Previous studies of this type of head and necl cancer have shown high rates of cancer control but result in many short and long term side effects when treated with high dose radiation and chemotherapy. Recently, investigators have noticed similar high rates of cancer control in small numbers of patients who receive less intensive treatments using lower doses of radiation, smaller radiation fields with chemotherapy. It is expected that the side effects of treatment with lower doses of radiation would be less. For this reason this study is looking at a different regimen of reducing the intensity of the treatment. The purpose of this study is to compare any good and bad effects of using lower dose smaller fields radiation therapy and chemotherapy with published outcomes. This study will allow the researchers to know whether these different approaches are better, the same, or worse than the usual approach. To be better, the study approach should result in the same survival rate of the usual approach (about 85 out of 100 patients alive and free of cancer at 2 years) but with less long-term side effects.

Interventions

  • RADIATION Modified dose and fields intensity modulated radiotherapy

Study Locations (1)

Florida

  • Baptist MD Anderson Cancer Center - Jacksonville

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-05-15
Est. Completion 2026-09-30
Phase NA

Sponsor

Omar Mahmoud

1 total trials

What the Registry Record Tells You About NCT06309225

The ClinicalTrials.gov registry entry for NCT06309225 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,506-participant average among 48 other Frailty trials with a reported enrollment target (99% lower). The listed sponsor is Omar Mahmoud, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Frailty appearing as the primary indexed condition, and to 1 intervention - of which Modified dose and fields intensity modulated radiotherapy is the first listed.

NCT06309225 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06309225 about?

NCT06309225 is a clinical study titled "Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly". Previous studies of this type of head and necl cancer have shown high rates of cancer control but result in many short and long term side effects when treated with high dose radiation and chemotherapy. Recently, investigators have noticed similar high rates of cancer control in small numbers of pati...

What is the current status of trial NCT06309225?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-05-15. Estimated completion is 2026-09-30.

What conditions does trial NCT06309225 study?

This clinical trial studies the following conditions: Frailty, Oropharynx Cancer.

What interventions are being tested in trial NCT06309225?

The interventions under investigation include: Modified dose and fields intensity modulated radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT06309225?

This trial is sponsored by Omar Mahmoud, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06309225 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Frailty

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.